One of the two digital health companies in Boomtown’s current health-tech class, cliexa develops mobile applications that assist users in managing their chronic diseases.
cliexa-Protocols, web-based disease management system is a member of cliexaTM family of products which is a data and algorithm hub. It provides decision support to physicians and other healthcare providers during the treatment process and optimizes treatment methods based on evidence-based knowledge and data.
cliexa-Protocols has started as a pilot program, developed and evolved in early 2014. It was recognized and initiated letter of intents by multiple healthcare provider firms as well as specialty pharma focusing on Hyponatremia and Hep C treatments.
In December 2013, CN4CE Inc. has submitted a 513(g) application for cliexa-Protocols. After reviewed by FDA, FDA confirmed that cliexa-Protocols Disease Management System is a medical device as defined in section 201(h) of the Act.
On May 10, 2016, cliexa-Protocols has received a confirmation from FDA for 513(g) application as cliexa-Protocols will not be enforced any regulatory requirements under applicable provisions of the Section 513(g) Act, including premarket notification, and its implementing regulations, in accordance with the Mobile Medical Applications Guidance.
Newswire Official Press Release
cliexa hosted a booth at Rocky Mountain Gastroenterology’s 15th Annual Pow Wow Conference on Saturday, April 9, 2016. Conference was held at Hyatt Regency at Denver Tech Center, Denver, CO.
The GI Pow Wow is designed to provide a gastroenterology & hepatology update to community primary care providers, surgeons, specialists, as well as medical oncologists & radiologists from throughout Colorado and the surrounding region.
Topics included:
- Opioid receptors & implications on treating Intestinal Disorders
- Childhood Obesity & Fatty Liver Treatment
- IBD Treatment update
- HCV update
- Esophageal Cancer Prevention
- Drug-Induced Liver Disease
At a conference with 400 healthcare industry providers, cliexa had a lot of visitors with lot of questions for cliexa-RA which is in Apple store and cliexa-IBD in early May 2016. Lots of physicians showed interest at scientific disease activity scoring which is tracked with both cliexa-RA and cliexa-IBD dynamically.
Our CTO Nathan Blair, CSO Esra Nutku-Bilir and myself have answered questions from different providers. cliexa-IBD for Inflammatory Bowel Disease is using a survey type disease activity scoring whereas cliexa-RA uses DAS28 joint point calculation.
cliexa-IBD has attracted lots of physicians, who are interested in EMR integration with their current systems which is now part of cliexa’s roadmap.
Here are some photos from the exhibition!
Mehmet Kazgan, CEO.
One of our partners, Lance Goudzwaard was in the news with //www.histalkpractice.com/.
Read his interview here:
//www.histalkpractice.com/2016/01/21/5-questions-with-lance-goudzwaard-coo-panorama-orthopedics-spine-center/